Published in Cancer Epidemiol Biomarkers Prev on November 01, 2002
Retracted Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer (2010) 1.69
Retracted Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res (2010) 1.51
Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res (2009) 1.15
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol (2009) 1.14
The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am (2012) 1.14
Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Br J Cancer (2006) 1.14
Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer. Proc Natl Acad Sci U S A (2011) 1.05
Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer. Invest New Drugs (2011) 1.02
Glycemic Index, Glycemic Load, and Lung Cancer Risk in Non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev (2016) 0.98
IGF-I and IGFBP-3 and the risk of lung cancer: a meta-analysis based on nested case-control studies. J Exp Clin Cancer Res (2009) 0.92
Association between circulating levels of IGF-1 and IGFBP-3 and lung cancer risk: a meta-analysis. PLoS One (2012) 0.91
Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res (2009) 0.87
Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer (2014) 0.83
Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology (2011) 0.82
Pre-analytic considerations for the proper assessment of hormones of the hypothalamic-pituitary axis in epidemiological research. Eur J Epidemiol (2006) 0.81
Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung Cancer. Malays J Med Sci (2016) 0.75
Is there a role for IGF-1 in the development of second primary cancers? Cancer Med (2016) 0.75
Cardiac-targeting magnetic lipoplex delivery of SH-IGF1R plasmid attenuate norepinephrine-induced cardiac hypertrophy in murine heart. Biosci Rep (2014) 0.75
The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells. Nat Commun (2016) 0.75
Insulin-Like Growth Factor I Receptor (IGF-IR) Ligands and BMI in Squamous Intra-Epithelial Lesion (SIL) of Cervix. J Clin Diagn Res (2016) 0.75
Serum Insulin, Glucose, Indices of Insulin Resistance, and Risk of Lung Cancer. Cancer Epidemiol Biomarkers Prev (2017) 0.75
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet (2011) 9.49
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet (2008) 5.43
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00
A risk model for prediction of lung cancer. J Natl Cancer Inst (2007) 4.25
Diabetes and cancer: a consensus report. CA Cancer J Clin (2010) 3.95
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst (2008) 3.67
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med (2012) 3.52
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst (2009) 3.48
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
The landscape of recombination in African Americans. Nature (2011) 3.06
Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst (2002) 3.03
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Stressing harms of physical inactivity to promote exercise. Lancet (2012) 2.93
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res (2008) 2.70
Metformin improves healthspan and lifespan in mice. Nat Commun (2013) 2.68
The collaboration readiness of transdisciplinary research teams and centers findings from the National Cancer Institute's TREC Year-One evaluation study. Am J Prev Med (2008) 2.64
Focus on bladder cancer. Cancer Cell (2004) 2.59
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Reliability and validity of self-report of vitamin and mineral supplement use in the vitamins and lifestyle study. Am J Epidemiol (2003) 2.38
Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res (2008) 2.37
Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res (2008) 2.37
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med (2008) 2.31
Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev (2005) 2.28
Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev (2003) 2.26
The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst (2004) 2.26
A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst (2004) 2.22
Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst (2008) 2.17
Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am J Epidemiol (2012) 2.16
Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst (2008) 2.15
Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila) (2008) 2.11
Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res (2008) 2.11
Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev (2003) 2.09
An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila) (2008) 2.05
Dietary phytoestrogens and lung cancer risk. JAMA (2005) 2.04
Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res (2005) 1.98
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer (2008) 1.96
Buccal cell DNA yield, quality, and collection costs: comparison of methods for large-scale studies. Cancer Epidemiol Biomarkers Prev (2002) 1.92
mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab (2013) 1.91
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene (2005) 1.89
A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila) (2011) 1.86
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res (2007) 1.82
Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr (2008) 1.80
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet (2012) 1.77
Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res (2008) 1.76
Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet (2013) 1.74
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet (2004) 1.70
Re: short telomere length, cancer survival, and cancer risk in 47 102 individuals. J Natl Cancer Inst (2013) 1.69
A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. PLoS Genet (2011) 1.68
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst (2014) 1.67
Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. J Clin Oncol (2011) 1.66
Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol (2007) 1.65
Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res (2010) 1.65
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol (2008) 1.64
Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila) (2010) 1.62
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer (2010) 1.61
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol (2009) 1.61
Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res (2004) 1.57
Insulin receptor expression by human prostate cancers. Prostate (2009) 1.57
Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol (2008) 1.55
Mediating effects of smoking and chronic obstructive pulmonary disease on the relation between the CHRNA5-A3 genetic locus and lung cancer risk. Cancer (2010) 1.55
Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst (2007) 1.53
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) (2011) 1.53
Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study. Ann Surg Oncol (2003) 1.53
Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. Carcinogenesis (2012) 1.52
Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the beta-carotene and retinol efficacy trial (CARET). Cancer Epidemiol Biomarkers Prev (2003) 1.51
Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. PLoS One (2011) 1.51
IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One (2008) 1.50
Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis (2010) 1.50
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res (2002) 1.48
Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res (2010) 1.48
Joint association of genome-wide association study-identified susceptibility loci and dietary patterns in risk of renal cell carcinoma among non-Hispanic whites. Am J Epidemiol (2014) 1.46
Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res (2009) 1.43
Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci U S A (2012) 1.43